
    
      This multicenter, randomized, double-blinded study was conducted during the 2014-2015
      Northern Hemisphere influenza immunization season to evaluate the non-inferior immune
      response of bioCSL QIV to that of bioCSL TIV-1 and bioCSL TIV-2 along with safety in healthy
      male and female adults aged â‰¥ 18 years. Each vaccinated subject had a maximum 25 day on-study
      period with a six month safety follow-up.
    
  